Perioperative myocardial ischemia reperfusion injury

Stanton K. Shernan, MD

Although advances in anesthetic and surgical techniques currently allow most patients to undergo coronary artery bypass grafting (CABG) procedures without significant mortality, more than 25% of this surgical population may still experience substantial morbidity related to adverse perioperative cardiovascular outcomes [1–4]. Stroke, myocardial infarction (MI), ventricular failure, and perioperative dysrhythmias can directly affect the length of hospital stay, the cost of hospitalization, and the functional capacity of the patients at discharge, and can ultimately contribute to mortality [4].

The etiology of myocardial dysfunction after CABG is often multifactorial, yet frequently involves perioperative myocardial ischemia. The myocardium may be particularly susceptible to ischemia during CABG surgery because of underlying coronary artery disease (CAD), perioperative hemodynamic instability, inadequate protection during cardiopulmonary bypass (CPB), coronary artery embolization, or technical complications (ie, incomplete revascularization and graft spasm or kinking). Although prolonged myocardial ischemia alone can jeopardize the structural and biochemical integrity of the cells, limited oxygen deprivation (<20 minutes) is usually associated with only transiently depressed myocardial contractility [5]. Paradoxically, the restoration of blood flow after sustained myocardial ischemia (>45 minutes) results in a phenomenon known as myocardial ischemia reperfusion (I–R) injury, wherein the tissue injury after reperfusion is greater than that produced by ischemia alone.

Perioperative myocardial I–R injury involves the generation of reactive oxygen species (ROS) on the restoration of oxygen (O2) delivery and alterations...
in intracellular calcium (Ca$^{2+}$) homeostasis. In addition, the activation of several proinflammatory pathways, including the complement, coagulation, and cytokine cascades, can exacerbate tissue injury and the functional impairment initiated by the original ischemic insult [6]. Thus, myocardial I–R injury involves a complex pathophysiologic process that contributes significantly to perioperative cardiac dysfunction and associated morbidity. Therefore, a significant effort has been made to develop novel surgical techniques and pharmacologic agents that may reduce the generation and subsequent pathophysiologic consequences of proinflammatory mediators. In this article, the pathophysiological mechanism and therapeutic interventions directed toward preventing and treating perioperative myocardial I–R injury is reviewed.

Pathophysiology of ischemia-reperfusion injury

Intracellular high-energy phosphate depletion

Prolonged ischemia results in a variety of cellular metabolic and ultrastructural changes initiated by a depletion in high-energy phosphates [7]. The absence of normal oxidative phosphorylation within the mitochondria leads to diminished myocardial tissue concentrations of adenosine 5′-triphosphate (ATP) and creatine phosphate. Depletion of adenine nucleotides may persist for hours to days after severe ischemia, partially due to the myocardium’s limited capacity for de novo purine synthesis. Initially, when ATP use exceeds the capacity of the myocytes to resynthesize high-energy phosphates, degradation of adenine nucleotides results in the conversion of adenosine diphosphate (ADP) to adenosine monophosphate (AMP). Further sustained reductions in ATP availability result in irreversible myocyte injury associated with sarcolemmal damage, acidosis, and cellular swelling, because ATP-dependent ionic pump function becomes compromised favoring extracellular leakage of potassium (K$^+$) ions and intracellular entry of Ca$^{2+}$, sodium (Na$^+$), and water [8].

Myocardial ischemia is also associated with an accumulation of intracellular lactic acid [9]; a decline in fatty-acid oxidation, which normally provides 60% to 90% of myocardial energy requirements [10]; and a depletion of glutathione, an endogenous intracellular antioxidant [7]. Finally, the characteristic changes in myocardial protein production and degradation may be acute or delayed, which suggests that altered genetic expression of protein synthesis may play a role in I–R injury [11].

Reactive oxygen species

Reperfusion of ischemic tissues results in the formation of toxic ROS, including superoxide anions (O$_2^-$), hydroxyl radicals (OH$^-$), hypochlorous acid (HOCl), hydrogen peroxide (H$_2$O$_2$), and nitric oxide (NO)- derived peroxynitrite [12]. Normally, hypoxanthine produced from AMP metabolism is further metab-
olized by xanthine dehydrogenase (XD) to xanthine [13]. During ischemia however, XD is converted to xanthine oxidase (XO) by Ca$^{2+}$-dependent proteases. Unlike XD, which uses nicotinamide adenine dinucleotide (NAD) as an electron acceptor during oxidation of xanthine, XO uses O$_2$. During O$_2$ deprivation, XO is unable to catalyze the conversion of hypoxanthine to xanthine, resulting in the accumulation of excess hypoxanthine. Subsequently, the reintroduction of O$_2$ during reperfusion permits the formation of ROS from the XO-mediated conversion of excess hypoxanthine and residual xanthine. Although the human myocardium may not have significant quantities of XO, ischemia-induced ROS can be generated by way of the NADPH oxidase system located in polymorphonuclear leukocyte (PMN) cell membranes, dissociation of mitochondrial electron transport, catecholamine auto-oxidization, and free metal ions [7].

The ROS are potent oxidizing and reducing agents that can directly damage cellular membranes, mitochondria, and the sarcoplasmic reticulum, resulting in depressed contractile function [14]. Histologic examination demonstrating evidence of myocardial contraction-band necrosis is the hallmark of ROS involvement in the “oxygen paradox” associated with I–R injury [5]. ROS also indirectly induce leukocyte activation and chemotaxis, by way of Ca$^{2+}$-mediated activation of plasma membrane phopholipase A2, which form arachidonic acid, an important precursor for eicosanoid synthesis [14,15]. Furthermore, ROS can directly activate complement components and may be responsible in part for the microvascular inflammation that is associated with an imbalance between endothelial cell production of NO and H$_2$O$_2$. Finally, ROS stimulate endothelial cell adhesion molecules and cytokine gene expression by way of activation of nuclear transcription factors, such as nuclear factor (NF)-$\kappa$B; in turn, these transcription factors are activated by oxidant stress [5,13–15]. Thus, ROS play a significant direct role in early cellular damage during I–R injury and indirectly stimulate the proinflammatory mediators responsible for further sustained myocardial dysfunction.

**Alterations in calcium homeostasis**

A “calcium paradox” has also been proposed as a potential mechanism for myocardial I–R injury [5,16]. While the membrane ATP-dependent ionic pump is initially impaired during myocardial ischemia, cytosolic Ca$^{2+}$ and Na$^+$ concentrations increase. When O$_2$ delivery is restored, subsequent mitochondrial oxidative phosphorylation reactivates the sarcoplasmic reticulum (SR) Ca$^{2+}$ pump (Ca$^{2+}$-ATPase) and the sarcolemmal Na$^+$ pump (Na$^+$-K$^+$-ATPase). The coordination of these two major cation pumps with the sarcolemmal Na$^+$/Ca$^{2+}$ exchanger normally helps to restore ionic gradients. In the presence of intracellular Ca$^{2+}$ overload however, excessive Ca$^{2+}$ sequestration in the SR can cause spontaneous oscillations and cardiac muscle hypercontracture, especially when energy is concurrently restored to the myofibrillar elements. Ultimately, substantial cytoskeletal structural injury causes an irreversible state of hypercontracture-induced sarcomere shortening. The contractile elements eventually become insensitive to calcium (ie, “calcium paradox”), which results in an overall
decrease in myocardial contractility [5,17]. During reperfusion, sarcolemmal stability may also be compromised by excessive water influx and cellular swelling associated with a persistent cytosolic Na\(^+\) overload in the presence of a rapidly normalizing extracellular osmotic load [16,18].

Although intracellular Ca\(^{2+}\) overload and ROS can independently contribute to myocardial I–R injury, the pathophysiologic mechanisms are not mutually exclusive. Intracellular Ca\(^{2+}\) overload is exacerbated during reperfusion by ROS, which interfere with Ca\(^{2+}\) flux at the level of the cell membrane or SR, directly compromise mitochondrial oxidative phosphorylation, and they irreversibly inhibit anaerobic glycolysis [10]. Alternatively, Ca\(^{2+}\)-dependent mechanisms promote ROS production by way of protease-mediated XO activation and by damage to the mitochondrial electron transport chain, which facilitates ROS leakage [10]. Thus, ROS and intracellular Ca\(^{2+}\) overload are important preliminary mediators of myocardial I–R injury.

Role of endothelial cell–leukocyte interactions

The endothelium plays an essential role in maintaining vascular homeostasis and is particularly vulnerable to the deleterious effects of ischemia and reperfusion injury [13]. Sustained hypoxia interferes with normal transcellular ion and water fluxes, thereby inducing ionic-potential imbalances, cellular edema, and eventual damage to the endothelial cytoskeletal integrity. After prolonged ischemia, the depletion of endothelial energy stores initiates microvascular injury. In addition, endothelial production of certain bioactive agents (eg, endothelin, thromboxane A2 [TxA2]) and proinflammatory gene products (eg, leukocyte adhesion molecules, cytokines) is enhanced, while endothelial cell production of other “protective” gene products (eg, constitutive NO, thrombomodulin) and bioactive agents (eg, prostacyclin, NO) is suppressed [13]. Thus, endothelial ischemia induces a proinflammatory state.

Normal endothelial cell function is further compromised after reperfusion because of the exacerbation of the pathophysiologic processes that began during the initial ischemic insult (Fig 1). ROS play a major role in the pathophysiology of this process.

Fig. 1. Endothelial cell-leukocyte interactions during ischemia-reperfusion (I–R) injury. Endothelial cell exposure to ischemia and the restoration of oxygen delivery (O\(_2\)), results in the intracellular production of reactive oxygen species (ROS: O\(_2\); H\(_2\)O\(_2\)). Subsequent endothelial cell activation involves multiple signal pathways resulting in decreased production of nitric oxide (NO), increased intracellular calcium (Ca\(^{2+}\)) concentrations, and increased production of mediators, including platelet activating factor (PAF) and leukotrienes (LTB\(_4\)). In addition, the surface expression of selectins (P-selectin, E-selectin) and intercellular adhesion molecules (ICAM, VCAM) is accelerated. Following activation by cytokines and activated complement components (C5a), leukocytes accumulate at the endothelial cell surface and begin loosely adhering or “rolling” by way of the interaction of the selectins (P-selectin, L-selectin). Firm adherence involves interactions between leukocyte \(\beta_2\)-integrins (CD11a/CD18; CD11b/CD18) and intercellular adhesion molecules. Leukocyte transmigration within endothelial cell junctions is mediated by platelet-endothelial cell adhesion molecule (PECAM), and results in the release of destructive ROS, proteases, and arachidonic acid metabolites (AAM).
of endothelial I–R injury. Restoration of O2 flow during reperfusion results in an accumulation of endothelial XO and in the subsequent production of excessive O2 and H2O2, as well as the ROS generated by locally activated leukocytes. In addition, Ca2+-dependent endothelial NO-synthase activity decreases after I–R injury, leaving little NO to scavenge the accumulating O2 [13]. Diminished endothelial NO is responsible for impaired NO-mediated arteriolar smooth muscle relaxation, enhanced platelet aggregation, leukocyte endothelial cell adhesion, and promotion of the capillary filtration response to I–R injury. ROS also promote leukocyte-endothelial cell interactions by mediating the expression of endothelial adhesion molecules, promoting the activation and deposition of complement on endothelial cell membranes, and enhancing phospholipase A2-mediated production of leukotrienes (LTB4) and platelet activating factor (PAF) [13].

Circulating leukocytes that have been activated systemically (eg, multisystem organ dysfunction, circulatory shock, aortic occlusion-reperfusion, and CPB), or remotely in combination with proinflammatory mediators (eg, tumor necrosis factor α, interleukin-1[IL-1], thromboxane B2 [TxB2], activated complement fragments, and PAF) may play a role in augmenting myocardial I–R injury [19]. Local neutrophil accumulation at the site of myocardial I–R injury however, represents one of the most important components of the overall pathologic process. The neutrophils and the vascular endothelium are involved in establishing a localized chemotactic factor concentration gradient involving complement fragment C5a, IL-8, transforming growth factor (TGF-α), and tumor necrosis factor (TNF) [5].

The neutrophil–endothelial cell interaction involves a sequential progression of steps (Fig 1). The first phase, which involves initial “rolling” and loose adherence of neutrophils to the endothelial surface, is promoted by selectin adhesion molecules, including L-selectin (LECAM-1), P-selectin (GMP-140), and E-selectin (ELAM-1) [5]. L-selectin is constitutively expressed on the surface of neutrophils and monocytes. P-selectin is constitutively synthesized and stored in Weibel-Palade bodies and can be rapidly mobilized to the cellular surface of platelets and endothelial cells in response to inflammatory mediators, such as ROS. L-selectin and P-selectin interact with corresponding cellular surface counter-receptors or ligands composed of the carbohydrate moieties sialyl Lewis X (sLeX) and A (sLeA). L-selectin and P-selectin adhesion molecules have an early role in establishing intermittent leukocyte-binding or “rolling,” which tethers neutrophils to the endothelial cell surface, and it leads to PAF-mediated activation [20]. Monoclonal antibodies (MAbs) directed against either P-selectin, L-selectin, or a sLeX-containing oligosaccharide have been shown to prevent neutrophils from adhering to the coronary endothelium, preserve coronary endothelial function, and attenuate myocardial necrosis after myocardial ischemia and reperfusion [21]. E-selectin is synthesized transiently and is transported to the endothelial cell surface after oxidant-dependent activation of nuclear transcription factors. Compared with the early involvement of L-selectin and P-selectin, E-selectin does not appear to play a sig-
significant role in myocardial I–R injury, at least within the first 5 hours of reperfusion [5,22]. The transition from neutrophil “rolling” on the endothelial surface to sustained adhesion involves the mobilization and up-regulation of neutrophil CD11/CD18 β2 integrins, mediated by PAF in conjunction with P-selectin (Fig 1) [23]. During reperfusion, β2 integrins bind acutely to endothelium-associated complement opsonizing particle, iC3b, to establish firm adhesion. However, further interactions between β2 integrins and endothelial-derived intercellular adhesion molecules (ICAMs) also mediate firm adhesion and permit further neutrophil recruitment in later phases. In an experimental model of myocardial I–R injury, anti-CD11b MAbs have been shown to reduce leukocyte adhesion and limit MI size [24].

The final phase of neutrophil–endothelial cell interactions involves diapedesis, or trans-endothelial migration of neutrophils through gap junctions between adjacent cells (Fig. 1). Neutrophil transmigration into the interstitial compartment is facilitated by platelet–endothelial cell adhesion molecule-1 (PECAM-1), which is constitutively expressed along endothelial cell junctions [25]. On reaching the extravascular compartment, activated leukocytes release toxic ROS and proteases (eg, collagenase and elastase), resulting in increased microvascular permeability, edema, thrombosis, and parenchymal cell death. Thus, neutrophil–endothelial interactions play a significant role in myocardial I–R injury and involve a complex progression of steps that require several proinflammatory mediators.

Role of the complement system

The complement system is a major component of the humoral immune system and plays a critical role in some of the inflammatory events occurring in myocardial I–R injury [26–28] (see article: “The System Inflammatory Response in Cardiopulmonary Bypass”). This innate cytotoxic defense system is composed of a catalytic cascade of approximately 20 intravascular proteins. A variety of immunologic processes are used to eliminate foreign cells, initiate inflammation, destroy pathogens, and disrupt cell membranes (Fig 2). The complement system is subdivided into three pathways: the classical, the alternative, and the lectin complement pathways. Activation of these pathways occurs sequentially through the proteolytic cleavage and association of precursor molecules. The classic complement pathway activation occurs when antibody/antigen complexes interact with the first complement component (C1) and ultimately cause the formation of the C3 convertase, C4b2a. The alternative complement pathway is antibody-independent and is activated by several mechanisms, including yeast cell walls (zymosan), biomaterials (eg, CPB circuits and hemodialysis tubing), and tissue type plasminogen activator [26–28]. Activation of this pathway leads to the formation of the C3 convertase, C3bBb. The recently described lectin complement pathway (LCP), also an antibody-independent pathway, is activated by binding mannose-binding lectin (MBL) to carbohydrate structures present on the surface
of bacteria, yeast, parasitic protozoa, and viruses [29]. Unlike the classic complement pathway, LCP activation does not require antibody, C1, or C1q deposition; instead, it relies on MASP-1 and MASP-2 to cleave C2 and C4 and form the classical C3 convertase.

All three complement pathways merge at C3, which is cleaved by the respective C3 convertase into the anaphylatoxic peptide C3a and the opsonic fragment C3b. C3a is a mast cell and eosinophil chemoattractant and activator [28,30]. Target cell attachment of C3b induces the formation of C5 convertase (C3b2Bb or C4b2a3b), which subsequently cleaves C5 into C5a and C5b. C5a promotes chemotaxis and activation of leukocytes and the generation of inflammatory mediators. C5b initiates the formation of C5b-9, the membrane attack complex (MAC), and induces targeted endothelial-cell production of chemokines (e.g., IL-8, monocyte chemoattractant protein-1) and expression of proinflammatory selectins and adhesion molecules [31]. Multiple target cell “hits” by the pore-forming C5b-9 promote water, electrolyte, and small molecule transcellular fluxes, ultimately resulting in cell lysis and irreversible tissue injury [28,30].

Evidence for the role of activated complement components in myocardial I–R injury includes the indirect effects of anaphylatoxins and the direct effects of C5b-9 in modifying leukocyte responses, altering vascular homeostasis, and
ultimately inducing tissue damage. Although reperfusion may further exacerbate the extent of complement-mediated myocardial injury, complement activation may actually be initiated during ischemia [28]. During ischemia, disruption of myocyte membrane integrity may allow intracellular entry and activation of complement components [30]. Exposed basement membranes, subcellular organelles, mitochondrial particles, cardiolipin, certain sensitizing antibodies, or the fibrinolytic system can each directly activate the classic complement pathway [32]. Activated complement components also play a role in modifying ROS production and Ca\(^{2+}\) flux that can contribute to myocardial I–R injury. For example, ROS generation can be directly promoted by way of C5a-induced conversion of XD to XO through endothelial interactions [33]. Ca\(^{2+}\) influx is also facilitated by complement activation by way of formation and membrane insertion of C5b-9 [34]. Thus, complement activation plays an important early role in modifying myocardial I–R injury.

Activated complement components are also particularly important facilitators of endothelial cell–leukocyte interactions and vascular injury. The anaphylatoxins C3a, C5a, and C4a act directly on smooth muscle to promote vasodilation [28,30]. In addition, anaphylatoxin-induced increases in vascular permeability are promoted by way of histamine release from mast cells and basophils, thereby facilitating neutrophil transmigration. C5a can independently promote neutrophil chemotaxis and aggregation and the production of ROS, arachidonic acid metabolites, and proteolytic enzymes. Also, C5a can modify neutrophil adherence to the endothelium by eliciting the release of PAF, which can subsequently activate neutrophils, up-regulate \(\beta_2\)-integrins, and induce L-selectin shedding [30]. Furthermore, C5a may amplify this inflammatory response by inducing cytokine production [30]. Formation of iC3b, resulting from C3b cleavage, has been demonstrated in vitro, with induction of IL-1 stimulated expression of ICAM-1 on endothelial cells [26]. Furthermore, iC3b functions as a specific ligand for the sustained adhesion of leukocytes to the vascular endothelium, by way of binding with \(\beta_2\)-integrins [5]. This facilitates the oxidative burst and release of proteolytic enzymes during neutrophil phagocytosis [28]. C5b-9 modifies neutrophil–endothelial cell interactions by stimulating production of endothelial von Willebrand factor and rapid translocation of P-selectin from Weibel-Palade bodies to the endothelial surface [30]. C5b-9 also activates endothelial NF-\(\kappa\)B, which increase transcription and expression of leukocyte adhesion molecules [35]. C5b-9 may also alter vascular tone by inhibiting endothelium-dependent relaxation and decreasing endothelial cyclic guanosine monophosphate [28]. Finally, C5b-9 promotes leukocyte activation and chemotaxis and triggers neutrophils to release ROS, proteolytic enzymes, and arachidonic acid metabolites (eg, LTB\(_4\), prostaglandin E2, Tx) [30].

Complement activation associated with myocardial I–R injury may also result from antibody-independent activation of the classical complement pathway at C2 and C4 levels by way of the LCP after MBL binds to cell-surface carbohydrates [29]. Although MBL does not normally recognize the body’s own tissues, oxidative stress may alter glycosylation of the cell surface membrane, which
leads to an increase in MBL deposition [26]. Thus, complement activation through any of the three delineated pathways may significantly contribute to the pathogenesis of myocardial I–R injury.

**Perioperative systemic inflammatory response syndrome**

During cardiac surgery requiring CPB, an imbalance in the systemic production of proinflammatory and anti-inflammatory mediators can contribute to organ dysfunction, which originates locally at the site of I–R injury [36]. The pathophysiology of this systemic inflammatory response syndrome (SIRS) involves several interdependent pathways, including the contact system, coagulation-fibrinolytic cascades, complement cascades, and cytokine production.

Several mechanisms have been proposed to account for the etiology of SIRS during cardiac surgery. Nonspecific activators include surgical trauma, blood loss or transfusion, and hypothermia. The inflammatory response can also be indirectly activated by increased systemic concentrations of endotoxin, associated with gut translocation after a mucosal barrier injury caused by splanchnic hypoperfusion [37]. In addition, heparin–protamine complexes can systemically activate inflammatory mediators (eg, complement, histamine, Tx, NO, and antibodies) [36]. Furthermore, inflammatory mediators generated at the site of I–R injury may also contribute to those that are circulating systemically.

During cardiac surgery, SIRS is profoundly affected by the exposure of circulating blood to the bioincompatible surfaces of the CPB extracorporeal circuit. This results in the generation of factor XII and activation of the intrinsic pathway of the coagulation cascade by way of the contact system [6]. The subsequent production of kallikrein activates the kinin–bradykinin system, stimulates C5a production, and leads to the generation of plasmin. Plasmin in turn activates the fibrinolytic system, generates additional contact activation proteins, and promotes C3 cleavage by way of the alternate complement pathway. The extrinsic pathway of the coagulation system is also activated in the perioperative period by the production of tissue factor from endothelium and muscle in response to surgical trauma, inflammatory stimuli, and oxidative or shear stress [36]. Thrombin produced from intrinsic and extrinsic coagulation pathways catalyzes the formation of insoluble fibrin from fibrinogen, which binds the platelet plug to initiate hemostasis.

In cardiac surgical patients, the normal balance of hemostasis is often disturbed. In the presence of significant vascular injury, the concomitant procoagulant activities of thrombin combined with the stimulation for fibrinolysis may become uncontrolled. Additionally, several coagulation proteins, including thrombin and Factor Xa, have proinflammatory properties [38]. Subsequent disseminated intravascular coagulation and microvascular occlusion may contribute to multiorgan dysfunction syndrome. Thus, the combination of endothelial cell, platelet and leukocyte activation, along with circulating cytokines and the procoagulants associated with SIRS, favors a systemic procoagulant/proinflammatory state that can exacerbate local I–R injury.
Treatment of perioperative myocardial ischemia–reperfusion injury

Myocardial I–R injury has been associated with transient reperfusion arrhythmias, myocardial stunning, and irreversible myocardial injury, all of which can contribute to perioperative morbidity and mortality [7]. Ideally, the morbidity associated with perioperative myocardial I–R injury may be diminished by limiting the duration and severity of the initial ischemic insult and by assuring timely reperfusion. However, the aortic cross clamping and CPB still required for the majority of cardiac surgical procedures subjects patients to varying degrees of multiorgan I–R injury. Furthermore, although extracorporeal circuit modification [39] and CABG without CPB (off-pump CABG, [OPCAB]) [40] may reduce inflammatory mediator generation, neither procedure guarantees that myocardial I–R and the associated perioperative morbidity will be entirely prevented.

Several modifications in cardiac surgical technique have been proposed in an attempt to either reduce the duration and severity of myocardial ischemia or reduce the generation of the systemic inflammatory mediators involved in I–R injury (Box 1). These techniques have included use of various cardioplegia recipes and delivery techniques, temperature regulation, CPB circuit modification, bilateral extracorporeal circulation, hemofiltration, leukocyte depletion, minimally invasive surgical techniques, and OPCAB [36]. Modifications of anesthetic techniques, including the use of thoracic epidural anesthesia and analgesia, have also been shown to attenuate the perioperative stress response and myocardial injury after CABG [41]. In addition, several anesthetic agents commonly used during cardiac surgery (eg, sodium thiopental, propofol, opioids, midazolam, and volatile agents) have systemic anti-inflammatory effects [36]. Myocardial gene delivery has also been proposed as a potential myocardial protection technique [42].

Most of the remaining therapeutic strategies have focused primarily on preventing or treating reperfusion injury by administering pharmacologic agents targeted at the most significant proinflammatory mediators associated with myocardial I–R injury, including those directed toward reducing exposure to endotoxins. Many of these proposed strategies have been limited to experimental and animal models of myocardial I–R injury. The following section focuses on pharmacologic interventions, having potential to reduce myocardial I–R injury, that have been investigated in clinical trials in cardiac surgical patients.

Myocardial preconditioning: ischemic and pharmacologic intervention

Ischemic preconditioning (IPC) refers to the phenomenon by which I–R injury can be diminished by prior exposure of the myocardium to repeated brief periods of ischemia [43]. Reimer et al [15] demonstrated that IPC of dog hearts slowed the consumption of high-energy phosphates. Further experimental investigation demonstrated additional myocardial benefits of IPC, including improved ventricular function, reduced myocyte apoptosis, and diminished neutrophil accumulation after I–R. Clinical trials using IPC have demonstrated less myocardial ATP depletion, lower troponin T levels, and a protective effect on
Box 1. Therapeutic strategies to attenuate perioperative myocardial ischemia-reperfusion injury

Surgical/procedural
- Cardiopulmonary bypass circuit modification:
  - Surface coating
  - Filters
  - Hemofiltration
  - Leukocyte depletion
  - Temperature
  - Pulsatile perfusion
  - Oxygenators: membrane versus bubble
  - Bilateral extracorporeal circulation
  - Minimally invasive techniques / OPCAB
  - Ischemic preconditioning
  - Thoracic epidural anesthesia

Endotoxin reduction
- Selective gut decontamination
- Anti-endotoxin antibodies
- Anti-endotoxin vaccine
- Immunonutrition
- Intravascular volume optimization

Pharmacological
- Monoclonal antibodies:
  - Cytokines
  - Complement
  - Adhesion molecules
- Platelet activating factor antagonists
- Endothelin receptor antagonists
- Aspirin-triggered lipoxin analogs
- Leukotriene antagonists
- Protease inhibitors
- Na⁺ /H⁺ exchange inhibitors
- NO- related therapy (L-arginine)
- Antioxidants
- Corticosteroids
- Calcium channel antagonists
- Pentoxifylline
- Pharmacological preconditioning

Myocardial gene therapy
- Direct transfection/transduction of genes or vectors
- Transducing cells

Abbreviations: OPCAB, “off-pump” coronary artery bypass graft surgery; NO, nitric oxide.
right ventricular contractility in patients undergoing CABG [44,45]. Factors such as the lack of consistency in the duration and number of IPC and reperfusion periods, the use of surrogate endpoints, ethical considerations involving the use of IPC in high-risk patients, and controversy over its benefit in “cardioplegia-protected” myocardium [46] however, have limited its widespread acceptance.

The IPC mechanism has been further delineated to reveal mechanisms of “early” and “delayed” myocardial protection, as well as the development of pharmacologic strategies that may provide a more practical means of preconditioning the myocardium (Fig 3). K⁺ ATP channel activation by way of isoflurane inhalation or morphine-mediated δ-1 opioid receptor activation, in addition to adenosine, bradykinin, acetylcholine, catecholamines, and myriad other agents, may also promote myocardial preconditioning [43].

Acadesine

Adenosine and adenosine-regulating agents are recognized for their potential role in mitigating myocardial ischemia [3,47]. The myocardial protective effect of adenosine is mediated through the K⁺ ATP channel by way of protein kinase C-dependent process [43,47]. Acadesine is a purine nucleoside analog that selectively increases tissue adenosine concentrations during myocardial ischemia. Data from experimental and animal studies demonstrate the beneficial effects of acadesine on postreperfusion ventricular function and dysrhythmias, platelet adherence, and granulocyte accumulation [3]. The effect of acadesine on perioperative MI, stroke, and death was evaluated in a meta-analysis of 5 randomized trials involving 4043 patients undergoing CABG surgery [3]. Acadesine treatment before and during surgery decreased the incidence of the perioperative MI by 27%, decreased cardiac death on postoperative day 4 by 50%, and decreased the composite outcome (MI, cardiac death, or stroke) by 26%. Although routine use of acadesine remains controversial [48], the potential benefit as a perioperative myocardial protective agent warrants further investigation.

Aprotinin

Serine proteases play a central role in the amplification of the contact activation, coagulation, and complement cascades. Consequently, serine protease inhibition may limit systemic generation of inflammatory mediators and similar processes related to local I–R injury in the perioperative period. Aprotinin is a nonspecific serine protease inhibitor that limits excessive blood loss and transfusion requirements in patients undergoing cardiac surgery [49]. In addition, a variety of anti-inflammatory effects have been attributed to aprotinin, including inhibition of platelet activation, leukocyte activation and adhesion molecule expression, contact activation, pro-inflammatory cytokine production, and complement activation [50]. Thus, the administration of aprotinin would be expected to have beneficial effects on perioperative myocardial I–R injury.

Clinical studies have demonstrated that aprotinin is associated with a reduction in post-CPB inotropic support [51] and cardiac enzyme release [52]. Furthermore, in a randomized trial involving 400 cardiac surgical patients and 4 “anti-inflamma-
tory” strategies (heparin bonded-circuit, leukocyte depletion, “standard” methyl-prednisolone, and aprotinin), aprotinin therapy was associated with the greatest reduction in length of hospital stay and cost in the high-risk subgroup [53]. Thus, in the cardiac surgical population, aprotinin does indeed have potential benefits for reducing blood loss and myocardial I–R injury by way of anti-inflammatory serine protease inhibition.

Corticosteroids

Corticosteroids are often considered the gold standard of anti-inflammatory agents. Corticosteroids may protect against myocardial I–R injury by reduced complement activation, diminished proinflammatory (TNF-α, IL-1β, IL-6, and IL-8) and increased anti-inflammatory (IL-10) cytokine production, attenuated leukocyte activation and adhesion molecule expression, and sequestration [54]. Several clinical studies have suggested that pre-CPB administration of corticosteroids is associated with improved cardiovascular performance and reduced perioperative morbidity [55]. However, the theoretical risk of increased infection and poor wound healing, in addition to the controversy regarding efficacy and dosing regimens, have limited the routine perioperative use of corticosteroids [36].

ROS scavengers and antioxidants

ROS are produced in significant quantities during I–R and play a major role in cellular injury. Protective endogenous myocardial antioxidants, including glutathione reductase, superoxide dismutase, and catalase can become depleted in the presence of overwhelming ROS generation, thereby reducing natural defenses and scavenging capacity. Thus, the use of exogenous free radical scavengers and antioxidants may be useful for ameliorating the deleterious consequences of I–R injury [36,56].

Fig. 3. Signaling mechanisms involved in myocardial preconditioning. Ischemia-induced activation of adenosine A1-receptors, eventual K⁺_ATP channels activation and a decrease in intracellular calcium (Ca²⁺), is responsible for the “early preconditioning” (1–2 hours) phase of cardioprotection. Induction of new protein synthesis including heat shock proteins (HSP), nitric oxide (NO), and antioxidants (SOD: super oxide dismutase) by way of the promotion of gene transcription is responsible for a “delayed, second window of myocardial protection” (SWOP), which reappears 12 to 24 hours after reperfusion. Receptor activation by several different agents (bradykinin, opioids, catecholamines, isoflurane) may permit pharmacological preconditioning through similar intracellular signaling mechanisms. ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate; B₂: bradykinin receptor type 2; δ: opioid delta receptor; α: alpha adrenergic receptor type 1; A₁/A₃: adenosine receptor types 1 and 3; G: G regulatory protein; PLC/PLD: phospholipase C and D; PIP₂: phosphoinositol biphosphate; DAG: diacylglycerol; PKC₁ and PKC₄: protein kinase C inactive and active forms; sKATP: sarcolemmal, ATP-dependent, potassium channel; mKATP: mitochondrial, ATP-dependent, potassium channel; TyK: tyrosine kinase; MAPK: mitogen activated protein kinase; NF-κB: nuclear factor kappa B; iNO: inducible nitric oxide synthase. (From Chen V, Body S, Shernan S. Myocardial preconditioning: characteristics, mechanisms, and clinical applications. Sem Cardiothorac Vasc Anesth 1999;3:85–97; with permission.)
Although several antioxidants have been investigated in experimental models of myocardial O$_2$ deprivation and have been shown to successfully salvage myocardium or to attenuate the sequelae of myocardial ischemia, there is a relative paucity of clinical data demonstrating their benefits [57]. Several commonly encountered agents, however, may have some beneficial antioxidant properties. Natural antioxidants such as vitamin C (ascorbic acid) and E (α-tocopherol) have been shown to effectively scavenge ROS and improve cardiovascular function after CABG surgery [56]. Allopurinol, a potent XO inhibitor, has also been associated with myocardial protection in cardiac surgical patients, although its efficacy remains controversial [36,58]. In addition, mannitol, by virtue of its many hydroxyl groups [56], has been shown to attenuate ROS generation during cardiac surgery requiring CPB [36]. Finally, some commonly used cardiovascular agents, including the β-blocker propanolol, calcium channel antagonists, and angiotensin-converting enzyme inhibitor, also have cytoprotective antioxidant properties [7,56]. Nevertheless, clinical studies attempting to preserve perioperative myocardial function by diminishing reduced-oxygen intermediates have generally yielded equivocal results.

**Complement inhibition**

Delineation of the complement cascade components, endogenous regulatory mechanisms, and interactions between different pathways has provided the foundation for developing novel pharmacologic strategies aimed at reducing myocardial I–R injury and its associated morbidity [27]. Although a variety of complement inhibitors have been developed, most investigations have been limited to animal and experimental models of extracorporeal circulation and I–R injury. However, a few of these agents have been investigated in the clinical environment. Nafamostat, a broad spectrum synthetic serine protease inhibitor of C1s, Factor D, and the C3/C5 convertases has been shown to decrease serum complement hemolytic activity and IL-6 and IL-8 production in patients undergoing CPB [59]. C1 esterase inhibitor (C1-INH) was administered as “rescue therapy” in three patients who became hemodynamically unstable after failed percutaneous angioplasty, and consequently required emergent surgical revascularization [60]. Hemodynamic stability was achieved in all 3 patients within 24 hours of drug administration, suggesting that myocardial I–R may be attenuated by inhibition of the classic or LCP.

To date, two complement inhibitors (soluble CR1 [sCR1] and a monoclonal anti-C$_5$ antibody [Pexelizumab]) have been administered to cardiac patients in large-scale clinical trials. Soluble CR1, an inhibitor of the C3/C5 convertases and cofactor of C3b and C4b inactivation, attenuates myocardial I–R injury in animals and reduces systemic inflammation in cardiac surgical patients undergoing CPB [27]. A recently terminated randomized, double-blinded, placebo-controlled trial involving the administration of a recombinant form of sCR1 (TP10: AVANT Immunotherapeutics, Inc.; Needham, MA) to 564 high-risk cardiac surgical patients, however, failed to demonstrate any benefit on the primary endpoint of death, MI, prolonged ventilation, or prolonged requirement.
for intraaortic balloon counterpulsation (AVANT Immunotherapeutics, Inc.; Needham, MA, Press Release, 2/20/02). A humanized, single chain, monoclonal anti-C5 antibody (Pexelizumab: Alexion Pharmaceuticals, Inc. Cheshire, CT) was also investigated in a Phase I, randomized, placebo-controlled trial involving 35 patients undergoing CABG surgery and who required CPB. Patients receiving the highest dose of pexelizumab (20 mg/kg bolus) demonstrated significantly attenuated complement activation, leukocyte activation, myocardial injury, blood loss, and cognitive dysfunction [61]. In a subsequent Phase II multicenter trial involving 914 patients undergoing CABG with or without valve surgery, a benefit in the primary composite endpoint (death; new Q-wave or non–Q-wave [CK-MB >60 ng/mL] MI; left ventricular dysfunction; and new central neurologic deficit) was not demonstrated between patients who received placebo versus those who received pexelizumab [62]. Post-hoc analysis revealed however, a significant reduction in the composite number of deaths or MIs (CK-MB ≥ 100 ng/mL) in the isolated CABG subgroup receiving bolus plus infusion of the study drug (2.0 mg/kg + 0.05 mg/kg infusion over 24 hours). The results of this trial have been used to establish the composite clinical endpoints for the cardiovascular and neurologic dysfunction in a larger scale Phase III trial, that is currently investigating the role of complement activation in CPB-induced systemic inflammation and I–R injury.

**Na+/H + exchange (NHE) inhibitors**

The NHE is a sarcolemmal protein that facilitates the exchange of intracellular H+ for extracellular Na+ [35]. Myocardial ischemia results in an increase in intracellular H+ that is exchanged for Na+ by activation of the dominant myocardial NHE isoform (NHE-1). The subsequent increase in intracellular Na+ promotes Na+/Ca2+ exchange, resulting in an accumulation of intracellular Ca2+ as the ATP-dependent Na+/K+ pump becomes dysfunctional. Excessive intracellular Ca2+ then facilitates myocyte injury. During sustained ischemia, NHE activity is usually self-limited because of the transmembrane ionic equilibrium that is eventually achieved, but reperfusion reestablishes an H+ concentration gradient from the intracellular to extracellular space, thereby promoting intracellular Ca2+ overload, which results in myocyte hypercontraction and cardiac dysfunction. Thus, NHE inhibitors such as cariporide and eniporide may attenuate myocardial I–R injury by preventing excessive intracellular Na+ and Ca2+ overload.

In a clinical trial involving more than 11,000 patients who received cariporide and who were at high risk for myocardial ischemia (ie, unstable angina, high-risk percutaneous angioplasty, high-risk CABG), no benefit was demonstrated for the primary endpoint (death or MI) or overall risk reduction [63]. However, CABG patients receiving the highest dose (120 mg every 8 hours for 2–7 days) experienced a 25% risk reduction and a 7% reduction in the incidence of non–Q-wave MI. In addition, the rate of Q-wave MI was reduced by 32% across all groups. The efficacy of cariporide in attenuating myocardial I–R injury is being further investigated in a high-risk CABG population.
Summary

Myocardial I–R injury contributes to adverse cardiovascular outcomes after cardiac surgery. The pathogenesis of I–R injury is complex and involves the activation, coordination, and amplification of several systemic and local proinflammatory pathways (Fig. 4). Treatment and prevention of perioperative morbidity associated with myocardial I–R will ultimately require a multifocal approach. Combining preoperative risk stratification (co-morbidity and surgical complexity), minimizing initiating factors predisposing to SIRS, limiting ischemia duration, and administering appropriate immunotherapy directed toward systemic and local proinflammatory mediators of I–R injury, should all be considered. In addition, the role of the genetic-environmental interactions in the pathogenesis of cardiovascular disease is also being examined. Thus, in the near future, preoperative screening for polymorphisms of certain inflammatory and coagulation genes should inevitably help reduce morbidity by permitting the identification of high-risk cardiac surgical patients and introducing the opportunity for gene therapy or pharmacogenetic intervention [42,64].
References


